Skip to content

Inspection Record

McKesson Corporation — FDA 483 Findings

US FDAInspected 2018-07-03Published 2019-04-30 3 findingsOther quality system

Inspectors Jolanna A. NortonThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Other quality system

The systems in place to enable compliance with the requirements of the Food Drug and Cosmetic Act Section 582 (c) are deficient: a.

2Other quality system

Failure to make a determination regarding product subject to an illegitimate product notification from a trading partner.

3Other quality system

Systems and procedures to make notifications following determination of an illegitimate product are deficient in that they do not instruct notifications to all immediate trading partners, and sufficient tracing information is not retained to identify trading partners that received such product.

A record as of the US FDA document published on 2019-04-30. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

McKesson Corporation company profile — full historyAll US FDA findings US FDA documents, 2019 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.